First-Line Regorafenib With Nivolumab and Chemotherapy for Advanced Oesophagogastric Adenocarcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial
Lancet Oncol 2023 Sep 01;[EPub Ahead of Print], SL Cytryn, RH Moy, D Cowzer, RH Shah, JF Chou, SS Joshi, GY Ku, SB Maron, A Desai, J Yang, R Sugarman, D Rao, Z Goldberg, C Charalambous, M Lapshina, A Antoine, F Socolow, N Trivedi, M Capanu, H Gerdes, MA Schattner, M Simmons, ME Lacouture, V Paroder, LH Tang, J Shia, DH Ilson, DB Solit, MF Berger, YY JanjigianFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.